- Active not recruitingPHASE3
Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa
This study is for people with moderate to severe Hidradenitis Suppurativa who have already been treated with Secukinumab in previous studies. It looks at whether continuing this medicine or stopping it works best long-term, and how safe it is.
For: Hidradenitis SuppurativaUnited States · Argentina · Australia - Recruiting
Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
This study investigates how inflammation, particularly involving a protein called IL-17, might link certain skin and joint conditions like psoriasis and psoriatic arthritis with depression. Researchers will use special brain scans and different anti-inflammatory medicines to understand and potentially improve depression symptoms.
For: Psoriatic Arthritis · Depression · Psoriatic PlaqueUnited Kingdom - Active not recruitingPHASE4
A Study of Secukinumab to Evaluate Maintenance of Response in Participants With Non-radiographic Axial Spondyloarthritis Who Achieved Remission
This study looks at whether people with a type of arthritis called non-radiographic axial spondyloarthritis need to keep taking a medicine called secukinumab to stay well once their symptoms have improved. It compares continuing secukinumab with switching to a dummy treatment.
For: Non-radiographic Axial SpondyloarthritisBelgium · Brazil · Colombia - Active not recruiting
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
This study looks at how a medicine called secukinumab is used in real life for adults with moderate to severe hidradenitis suppurativa (HS). It aims to understand treatment patterns and what influences dose decisions over two years in Germany.
For: Hidradenitis SuppurativaGermany - Active not recruitingPHASE3
Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
This study is looking at the long-term safety of a treatment called secukinumab for people with Polymyalgia Rheumatica (PMR). It's for those who have already been in a previous study for secukinumab and had their PMR symptoms come back after stopping treatment.
For: Polymyalgia RheumaticaUnited States · Argentina · Australia